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Objectives: To describe current real-world data on in-hospital/long-term mor-
tality and morbidity outcomes in patients in the western world with acute coro-
nary syndromes (ACS). MethOds: We conducted a review of publications from 
international registries: GRACE (Global Registry of Acute Coronary Events) and 
GRACE expanded (both worldwide); GRACE UK-Belgium; and EuroHeart survey II/III 
(Europe/Mediterranean basin). The most recent data on in-hospital/long-term out-
comes were stratified by ACS type: ST-elevation myocardial infarction (STEMI) and 
non-ST elevation Acute Coronary Syndromes (NSTE ACS), which includes unstable 
angina (UA) and the non-ST elevation myocardial infarction (NSTEMI). Results: 
In-hospital mortality rates were 4.6–7.8% in STEMI patients, 2.2–5.9% in NSTEMI 
patients, and 0.8–2.7% in UA patients. At 6 months post-discharge, mortality rates 
were 4.5–4.8% in STEMI patients, 6.2% in NSTEMI patients, and 3.6% in patients 
with UA. These rates increased to 19%, 22%, and 18% in STEMI, NSTEMI, and UA, 
respectively, at 5 years post-discharge. The most common morbidities were in-hos-
pital congestive heart failure (STEMI, 11–15%; NSTEMI, 6.1–10%; and UA, 6%) and 
in-hospital myocardial (re)infarction (STEMI, 2–2.8%; and NSTE-ACS, 1.7–2.4%). Six 
months post-discharge myocardial (re)infarction rates were 2% in STEMI patients 
and 2.9% in NSTE-ACS patients, which are lower than previously reported in clini-
cal trials. cOnclusiOns: Despite current treatments, a substantial proportion 
of patients with ACS still suffer death and serious morbidities in the acute phase 
of the disease and longer term. Further research is needed to improve acute and 
long-term therapies.
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Objectives: For patients with atrial fibrillation (AF) undergoing a surgery, guidelines 
recommend the interruption of VKA-treatment combined with LMWH/UFH bridging. 
As a result, patients may be placed at higher risk for thromboembolic events during 
this time. This study investigates the incidence of such perioperative management 
situations and describes clinical event rates. MethOds: Claims data from a large 
German statutory health insurance (period 01/01/2007-31/12/2011) was analysed. 
AF-patients who started VKA-treatment within this period and continued ther-apy 
until 31/12/2011 were included. VKA-interruption/bridging was assumed when the 
patient was admitted to a hospital due to an inpatient surgical procedure (case 1) or 
the patient experienced an outpatient surgery, combined with an outpatient pre-
scription of a LMWH/UFH within 10 days after surgery (case 2). Clinical events of 
interest were cardiovascular (strokes, TIA, embolism, myocardial infarctions) and 
bleedings leading to inpatient hospitalization. Daily event rates during regular VKA 
usage days were compared to those 5 days before/30 days after surgery (“interruption/
bridging days”). Results: 41,170 patients were included (mean age 74.8 years; 50.8% 
male; average CHA2DS2-VASc score 5.2). 11,695 (28.4%) VKA-patients experienced 
a hospital admission due to a surgery (case 1). 464 patients (1.1%) experienced an 
outpatient surgery with outpatient LMWH prescription (case 2). Overall (both cases) 
potential interruption/bridging occurred 0.24 times per person-year. The daily car-
diovascular/bleeding event risk during potential VKA-interruption/bridging was 
about 10fold/25fold higher than during a regular VKA-usage day (0.08%/0.21% vs. 
0.0078%/0.0083%, vs. (p< 0.0001)). About half of the bleedings were coded by treat-
ing physicians as due to anticoagulation therapy. cOnclusiOns: Periods in which 
VKA-interruption/bridging due to surgery was required frequently occur during 
the VKA-treatment of AF patients. The cardiovascular/bleeding event risk of VKA-
patients is significantly higher during such periods compared to periods of regular 
VKA-treatment. Whether this is due to VKA-interruption/bridging or the surgical 
procedures themselves needs to be analysed in future.
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Objectives: To explore the use of a cause-of-death-based mortality model to 
identify those individuals most likely to benefit from taking statins for primary 
prevention of cardiovascular disease (CVD). MethOds: A cause-of-death-based, 
deterministic Markov model of all-cause mortality was developed. The baseline 
population average mortality rates for CVD, COPD, other respiratory disease, and 
cancer were adjusted by referencing individual risk factor values to population 
averages. Risk factors that were used as model inputs included cigarette consump-
tion per day (CPD), systolic blood pressure (SBP), body mass index (BMI), total 
cholesterol (TC), and high density lipoprotein (HDL). A total of 11,520 scenarios 
were modelled encompassing all combinations of high and low values for these 
risk factors, in men and women, and younger (35 years) and older (65 years) age 
categories. Results: Using an arbitrary threshold for a meaningful clinical ben-
efit of 6 months’ increased life expectancy per 10 years of treatment, individuals 
who are on the cusp of benefiting from statin therapy include: men aged 35 with 
SBP of 150 mmHg, BMI of 20 kg/m2, smoking 15 cigarettes per day, with a TC:HDL 
ratio of 3.5; men aged 70 with SBP of 140 mmHg, BMI of 20 kg/m2, smoking 10 
cigarettes per day, with a TC:HDL ratio of 2.8; women aged 35 with SBP of 135 
mmHg, BMI of 20 kg/m2, smoking 15 cigarettes per day, with a TC:HDL ratio of 4.2 
or higher; and women aged 65 with SBP of 140 mmHg, BMI of 30 kg/m2, who are 
non-smokers, with a TC:HDL ratio of 4.2. cOnclusiOns: The model facilitates 
decision-making about when to start preventive treatment and highlights that 
this is a multi-dimensional problem that renders rules-of-thumb inadequate in 
determining who most benefits from therapy.
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Objectives: Diuretics are drugs of first choice in the treatment of hypertension. The 
aim of this study was to analyze the consumption of diuretics in Serbia in the period 
from 2007 to 2011 year. MethOds: The data about the use of drugs were taken 
from the Agency for Drugs and Medical Devices of the Serbia. Results: The use of 
diuretics during the observed period in Serbia is quite small and it ranged from 5 to 
6% of the total consumption of all drugs from the C group. Furosemide was the most 
frequently used diuretic. In the five year period furosemide consumption ranged 
from 33-55% of the total consumption of all diuretics. The second largest consupm-
tion during first four years of the study is belonged to the indapamide. Indapamide 
consumption in the fifth year was at the fourth position. At the third position in drug 
consumption in the first four years was hydrochlorothiazide. Use of hydrochloro-
thiazide in 2011 took second place. Spironolactone has occupied the fourth position 
in the first four years. During the last years of the period spironolactone occupied 
the third position. Consumption of all other diuretics was small. cOnclusiOns: 
In Serbia, in the observed period, consumption of diuterics is two to three times 
lower in comparison with the consumption of diuretics in Norway and Finland. 
This research was supported by Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and 
by Ministry of Science, Republic of Serbia, project no 41012.
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Objectives: Beta blocking agents are drugs of first choice in the treatment of 
hypertension. The aim of this study was to analyze the consumption of beta block-
ing agents in Serbia in the period from 2007 to 2011 year. MethOds: The data about 
the use of drugs were taken from the Agency for Drugs and Medical Devices of the 
Serbia. Results: During the observed period in Serbia the consumption of selective 
beta blocking agents were dominant. The most frequently used drug from this group 
was metoprolol. During this five years the consumption of metoprolol is in steadily 
decreased. In 2007. it was 37.73 DDD/1000 inh/day, at the end of 2011. year the con-
sumption was 22.13 DDD/1000 inh/day. On the second place in drug consumption in 
the same group of drugs was atenolol. Atenolol also recorded a decline in consump-
tion. On the third place in drug consumption was bisoprolol. At the beginning of 2007. 
consumption of this drug was very small, gradually grew and reached its maximum 
in 2011. From the unselective beta blocking agents the most frequently used was pro-
pranolol and his consumption in the observed years was constant. cOnclusiOns: 
In Serbia, in the observed period the consumption of beta blocking agents been 
mostly constant. From all drugs in C07 group the most frequently used group of 
drugs was C07AB. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 114-
451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
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Objectives: To systematically review the humanistic and economic burden of 
pregnancy-related venous thromboembolism (VTE). MethOds: Pubmed, Cochrane 
Central Register of Controlled Trials, Econlit, Science Direct, JSTOR, Oxford Journals 
and Cambridge Journals were searched using combinations of a considerable number 
of relevant words. Humanistic studies published from January 2000 to December 2012 
were eligible for inclusion in the review. The reference lists of all relevant papers 
retrieved from the original search were manually screened to identify additional 
studies. The identified studies were independently reviewed by two reviewers against 
pre-determined criteria. A quality assessment of the selected studies was also con-
ducted by using standard methods. The data of selected studies were extracted onto 
a data extraction form and consequently synthesized. Results: Twenty studies were 
included in our review. The overall pregnancy-related VTE incidence rate per 1,000 
deliveries ranged between 1 and 1.72. This rate was higher in the postpartum period 
compared to the antenatal period. Events were spread across the 3 trimesters, with 
the majority of events occurring in the third trimester of pregnancy. Limited data is 
available on mortality due to pregnancy-related VTE, with one study reporting an over-
all mortality rate of 1.1/100,000 deliveries due to pregnancy-related VTE. Recurrence 
rate was found to be higher in the postpartum period compared to the pregnancy 
period. Poorer quality of life (QoL) was identified in women with pregnancy-related 
VTE in comparison to their counterparts with no VTE. Data regarding the economic 
burden of VTE in this specific population was lacking. cOnclusiOns: The present 
systematic review showed that women are under a substantially increased risk of 
VTE events during pregnancy and VTE strongly affect their QoL. Despite the expected 
economic burden imposed by the pregnancy-related VTEs, no relevant studies were 
found. Therefore, further research is required to evaluate the humanistic and eco-
nomic burden of VTE in pregnant women.
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